Chapter 17 · Measurement, agreement and diagnosis
Is the laboratory result in control, and is it normal?
Levey-Jennings charts, Westgard rules, process capability and establishing reference intervals.
Read first: Descriptive statistics
The problem first
You are a first-year MD Biochemistry resident on the morning QC round. The level 1 glucose control reads 105 mg/dL. Its mean is 100 and its SD is 2.18, so the result is just beyond +2 SD. Yesterday it read 106.
The technician wants to release the ward samples because “it is only 2 SD”. Your consultant looks at the chart and asks one question.
“Which rule did it break, and is it random or systematic error?”
Start here
Why run a control sample when the analyser has already been calibrated?
A calibration is correct at the moment it is done. Reagents deteriorate, kit lots change, pipette calibration changes and operators change. A control sample with an expected value, run with the patient samples, shows whether the method is still giving the same answer today.
Internal quality control (IQC) is the sample material and procedures that verify that the intended quality of results has been reached, including monitoring the day-to-day reproducibility of results and detecting major errors in the analytical process. External quality assessment (EQA) is an external evaluation of a laboratory's performance using panel samples whose values are known to the organiser but not disclosed to the laboratory. Both definitions are from the NBTC operational guidelines for blood centres (2024).
Control materials
What makes a good control material?
A control material is a sample you run like a patient sample but whose expected range you have already established. It is useful only if it behaves like patient samples and tests the method where clinical decisions are made.
- Stable for the property being measured, so that changes on the chart come from the method and not from the control.
- Matrix as close as possible to patient samples, so that it reacts to the method in the same way.
- Concentrations at or near decision limits, and where possible covering the measuring range. In clinical chemistry, controls are usually available in two or three levels covering the medical decision points.
- Third-party material should be considered, instead of or in addition to controls from the reagent or instrument manufacturer.
- Lot changes kept apart: do not change the IQC lot on the same day or run as a reagent or calibrator lot change, otherwise a shift cannot be traced to its cause.
- For qualitative screening tests such as TTI ELISAs, a borderline-reactive control shows small changes that a strongly positive kit control does not.
Items 1 to 5 follow the IQC requirements in the NBTC operational guidelines (2024). Item 6 is from Dubey and Sonker (2021). Before plotting, establish the control's own mean and SD: Westgard QC recommends a minimum of 20 measurements over at least 10 days.
The chart
How do you draw a Levey-Jennings chart?
Measure the control at least 20 times to learn its usual mean and SD. Draw horizontal lines at the mean and at 1, 2 and 3 SDs above and below it. Then plot each new control result in time order.
Worked example 1: setting the limits
Made-up teaching data. Level 1 glucose control, 20 baseline results (mg/dL): 98, 101, 103, 99, 100, 97, 102, 104, 100, 96, 101, 99, 103, 98, 100, 102, 97, 101, 99, 100.
- Mean = 2000 ÷ 20 = 100.0 mg/dL.
- SD (dividing by n − 1 = 19) = 2.18 mg/dL. CV = 2.18 ÷ 100 × 100 = 2.2%.
- ±1 SD: 97.8 to 102.2. ±2 SD: 95.6 to 104.4. ±3 SD: 93.5 to 106.5 mg/dL.
Why 2 SD limits alone reject good runs
If the method is stable and results are normally distributed, one control falls beyond ±2 SD in 4.55% of runs and beyond ±3 SD in 0.27%. With two controls in a run, at least one falls beyond ±2 SD in 1 − 0.9545² = 8.9% of perfectly good runs. Westgard QC gives the same figure, about 9%, for a Levey-Jennings chart with 2 SD limits and N = 2. Limits at 3 SD reject far fewer good runs (0.54% with two controls) but detect fewer real errors. Multirule QC was designed to keep false rejections low while keeping error detection high.
Westgard rules
Which Westgard rule was broken, and what does it tell you?
Westgard, Barry, Hunt and Groth (1981) combined several control rules on one Levey-Jennings chart. Each rule looks for a different pattern, and the pattern suggests the type of error.
| Rule | Violated when | Usually indicates | Applied |
|---|---|---|---|
| 1-2s | One control result beyond ±2 SD | Warning: inspect with the other rules | Within the run |
| 1-3s | One control result beyond ±3 SD | Random error | Within the run, each material |
| 2-2s | Two consecutive results beyond the same +2 SD or the same −2 SD limit | Systematic error | Across the two materials in a run, or within one material across two runs |
| R-4s | One result beyond +2 SD and another beyond −2 SD | Random error | Within the run only |
| 4-1s | Four consecutive results beyond the same +1 SD or the same −1 SD limit | Systematic error | Across runs (and across materials) |
| 10x | Ten consecutive results on the same side of the mean | Systematic error | Across runs (and across materials) |
- Manual use: 1-2s is a warning that triggers inspection with the rejection rules. Computer use: the warning step is not needed, because the software can apply every rejection rule to every run.
- When only three control materials are run, rules that fit multiples of 3 are used instead: 2of3-2s, 3-1s, 6x or 9x. Variants 8x and 12x fit N = 4.
- Opening problem: runs 3 (105) and 4 (106) are both beyond +2 SD (104.4), so the 2-2s rule rejects run 4. Systematic error is the likely cause, and the ward samples should not be released.
Interactive
Add a shift or extra scatter and watch which Westgard rules reject the runs
A shift moves every result the same way, so rules that look at several results on one side (2-2s, 4-1s, 10x) react first. Extra scatter makes single extreme results and results on opposite sides more likely, so 1-3s and R-4s react.
Try this: set the shift to 2 SD and watch which rules reject the runs after run 16. Then set the shift back to 0 and the SD to 3 times, and see which rules react instead.
Teaching simulation with made-up data: two control materials (level 1 and level 2) run once each in 30 analytical runs, plotted as SD units from their own means. Runs 1 to 15 are in control. From run 16 the error you choose is added.
On: the rejection rules are checked only in runs with a result beyond 2 SD (the manual method)
● level 1 ○ level 2 red: results in a rule violation, labelled with the first rule broken
No error was added from run 16. In runs 1 to 15, when nothing was wrong, 0 of 15 runs were rejected. The 1-2s warning was triggered in 2 of 30 runs.
No run broke a rejection rule.
In a real laboratory you would stop at the first rejected run, correct the problem and start collecting control results again. This simulation keeps going so that you can see every rule that reacts.
Decide
A control result is outside its limits: what do you do?
Work through the rules in order. Every rejected run needs a cause, a correction and repeated patient samples.
Is either control result in this run beyond 2 SD from its mean?
Control result outside limits: all possible answers
- Accept the run: Report the patient results and plot the control values.
- Reject: 1-3s or R-4s, usually random error: Do not report patient results. Look for causes of scatter such as air bubbles, a clogged or loose pipette tip, poor technique or a sample mix-up. Correct, re-run the controls, then repeat the patient samples tested since the last acceptable control run.
- Reject: 2-2s, usually systematic error: Do not report patient results. Look for a cause that moves every result the same way: a new reagent or kit lot, calibration, a changed operator, deteriorated reagent or control material. Correct, re-run the controls, then repeat the affected patient samples.
- Reject: 4-1s or 10x, usually systematic error: A small shift has persisted over several runs. Check lot changes, calibration and storage of reagents and controls, then repeat the affected patient samples after correction.
- Accept, with a warning: No rejection rule is broken, so the run can be reported. Review equipment calibration, reagent and control handling, and the operator's technique, because an error may be starting.
After a rejection, patient results tested since the last successful IQC event must be evaluated (NBTC 2024). Results from before the correction are not used to apply the across-run rules again.
Comparison
Random or systematic error: how do they differ?
The two errors have different causes and different fixes. The rule that was broken points you to one kind of cause first.
| Feature | Random error | Systematic error |
|---|---|---|
| What it does | Results scatter unpredictably in size and direction | Results move consistently to one side (bias) |
| Measured as | SD or CV of repeated control results | Bias: difference from the target or peer-group value |
| Westgard rules | 1-3s, R-4s | 2-2s, 4-1s, 10x |
| Examples in an ELISA laboratory | Air bubble in washer tubing or pipette tip, clogged pipette, sample mix-up, poor technique | Change of kit lot, change of operator, inaccurate pipette calibration, deteriorated reagents or control material |
| How it is reduced | Training, strict SOPs and supervision. Repetition reduces its effect | Find the cause and correct it. It is amenable to correction |
| Feature | Control limits | Allowable total error (TEa) |
|---|---|---|
| Where it comes from | Your own control data: mean ± 2 or 3 SD | A quality requirement for the test |
| What it answers | Is today's run behaving like the method usually does? | Is the method good enough for clinical use? |
| Sources | Baseline control measurements | Clinical outcome studies, biological variation, or the state of the art (EQA and regulatory limits such as CLIA or RiliBÄK) |
| Changes when | The method's imprecision changes | The clinical requirement or the chosen source changes |
External quality assessment
What does external quality assessment show that your own controls cannot?
Your IQC chart compares your method with itself. If every result is 5% too high every day, the chart stays calm. EQA sends the same undisclosed sample to many laboratories and compares your result with theirs.
z = (x − μ) ÷ σ
- x
- your laboratory's result on the EQA sample
- μ
- mean of the EQA participants (the assigned value)
- σ
- SD of the EQA participants
Worked example 2 (made-up): your creatinine result is 1.32 mg/dL, the peer mean is 1.20 and the peer SD is 0.05. z = (1.32 − 1.20) ÷ 0.05 = 2.4. Peer-comparison reports use the same idea as the standard deviation index: SDI = (laboratory mean − group mean) ÷ group SD. An SDI within ±1.0 is acceptable, 1.0 to 1.9 means a problem may exist and should be investigated, and 2.0 or more calls for troubleshooting of bias and corrective action.
Proficiency testing is the structured evaluation of laboratory methods to assess the suitability of processes, procedures, equipment, materials and personnel. EQA providers do it by distributing material for testing. Interlaboratory comparison is the organisation, performance and evaluation of tests on the same or similar items by two or more laboratories under predetermined conditions.
| Feature | Internal quality control | External quality assessment |
|---|---|---|
| Sample | Control material run in your own laboratory | Samples supplied by an external agency, value not disclosed |
| How often | Every run, before patient results are released | At predefined intervals, for example once a month in clinical chemistry. NEQA for blood centres: at least three test events a year |
| Main question | Is this run acceptable? Is the method stable? | Does my result agree with other laboratories or the assigned value? |
| Main error shown | Imprecision (CV) and shifts over time | Bias |
| Statistic | Levey-Jennings chart and Westgard rules | z-score or SDI |
| Action | Immediate: hold or release today's results | Retrospective: investigate and correct the method |
India
What do India's operational guidelines for NEQA in blood centres require?
The Blood Transfusion Services division of the Directorate General of Health Services published Operational Guidelines for National External Quality Assessment Programme for Blood Centres in India, first edition 2024.
| Feature | What the guidelines say |
|---|---|
| Aims | Establish NEQA across blood testing centres, identify organising centres, evaluate performance systematically, identify common errors and provide corrective measures, harmonise testing |
| Structure | National coordinating centre (Dte.GHS), advisory committee, nodal centres acting as PT providers for two or more states, and a state representing blood centre (SRBC) in each state |
| PT providers | Must participate in an internationally accredited EQA programme for TTI serology and immunohaematology. Examples of sample providers: Indian Institute of Immunohaematology Mumbai, CMC Vellore, AIIMS New Delhi, PGIMER Chandigarh |
| Markers | TTI: anti-HIV 1 and 2, HBsAg, anti-HCV, malaria parasites, anti-Treponema pallidum. IH: ABO grouping, crossmatching, Rh(D) typing, antibody screening and identification, red cell phenotyping, DAT, haemoglobin |
| Frequency | At least three test events a year for both TTI and IH |
| Samples | TTI: 5 to 8 samples of 1.5 mL, each confirmed positive for one marker and negative for the rest. IH: at least two samples for ABO and RhD, and at least one serum with a clinically significant atypical antibody |
| Turnaround | At least 4 to 6 weeks from sample receipt to reporting of results |
| Pilot | One EQA cycle pilot in at least ten government licensed blood centres of different distance, size and technique |
| Scoring | TTI: 25 marks for test kit information and 75 for results (100). IH: 25 and 475 (500). z score for quantitative data |
| Performance | Define satisfactory, unsatisfactory and borderline performance. A false negative TTI result, and non-return or late return of results, are unsatisfactory. Use a non-punitive approach and cumulative scores |
| Follow-up | Contact to find the cause, then a letter to the head of the laboratory if there is no improvement, with training, extra EQA material or a supervisory visit |
| IQC | Participants must run IQC, record it so that trends and shifts are detectable, and prevent the release of results when IQC fails |
Sigma metrics
How many sigmas does your test have?
Decide how far a result may be from the true value (the allowable total error, TEa). Take away the bias. Count how many SDs of your method fit into what is left. That count is the sigma metric.
Sigma = (TEa% − |bias%|) ÷ CV%
- TEa
- allowable total error for the test, in percent
- bias
- systematic error, usually from EQA or peer-group data, as an absolute percentage
- CV
- imprecision from internal QC data, in percent
Worked example 3 (made-up): TEa 10%, bias 2%, CV 2%: sigma = (10 − 2) ÷ 2 = 4.0. With bias 1% and CV 1.5%: (10 − 1) ÷ 1.5 = 6.0. The quality goal index (QGI) = bias ÷ (1.5 × CV) shows why a method falls short: below 0.8 points to imprecision, above 1.2 to inaccuracy. For method A, QGI = 2 ÷ 3 = 0.67, so imprecision is the main problem.
| Sigma | Defects per million (short-term scale) | Westgard Sigma Rules, 2 control levels |
|---|---|---|
| 6 or more | 3.4 | 1-3s, N 2, one run |
| 5 | 233 | 1-3s / 2-2s / R-4s, N 2, one run |
| 4 | 6,210 | 1-3s / 2-2s / R-4s / 4-1s, N 4 in one run or N 2 in each of two runs |
| Below 4 | 66,807 at 3 sigma | Add the 8x rule: N 4 in each of two runs or N 2 in each of four runs |
The short-term scale assumes a later shift of 1.5 SD, so 6 sigma corresponds to 4.5 SDs and 3.4 defects per million. The same sigma can come out higher or lower depending on the TEa source chosen (CLIA, biological variation or RiliBÄK), so always state the source.
Interactive
Change TEa, bias and CV and watch the sigma metric and the suggested QC rules
Bias moves the curve towards one limit and CV widens it. Sigma counts how many SDs still fit between the bias and the TEa limit.
Try this: start at TEa 10%, bias 2% and CV 2% (sigma 4.0). Reduce the CV to 1.3% and watch the sigma pass 6 and the suggested QC change to a single 1-3s rule.
Teaching values. In your own laboratory the CV comes from internal QC, the bias from EQA or peer-group data, and TEa from the quality requirement your laboratory has chosen for that test.
How far a result may be from the true value
Systematic error
Random error
4.00 SDs of this method fit between the bias and the TEa limit. On the Six Sigma scale, which assumes a later shift of 1.5 SD, that corresponds to about 6,210 results per million outside TEa.
Suggested QC (Westgard Sigma Rules, 2 control levels): 1-3s / 2-2s / R-4s / 4-1s, with 4 control measurements in 1 run (N 4, R 1), or 2 in each of 2 runs (N 2, R 2).
quality goal index = 2.0 ÷ (1.5 × 2.0) = 0.67, below 0.8: the main problem is imprecision (CV)
Reference intervals
How is a reference interval established?
A reference interval describes the central 95% of results in carefully selected healthy people. It is built in four stages: selecting the people, collecting the samples, measuring them, and calculating the limits.
- Select reference individuals. Use a questionnaire with exclusion criteria (conditions that prevent inclusion) and partition criteria (age, sex). Obtain written informed consent. In a priori sampling, exclusions are applied before collection. In a posteriori sampling, after. Both are direct methods.
- Control pre-analytical factors. Biological: sampling time, fasting, physical activity. Methodological: collection technique, additives, tourniquet use, handling, transport, centrifugation time and speed, storage.
- Control analytical factors. Define the method, instrument, reagents and calibrators with traceability, and run a quality control programme with clear criteria.
- Analyse the values. Remove outliers (for example Dixon's D/R ratio above 1/3, or Tukey fences after Box-Cox transformation). Decide on partitions (for example a standard deviation ratio above 0.3). Take the 2.5th and 97.5th percentiles, with 90% confidence intervals for both limits.
The parametric method assumes a normal distribution (after transformation if needed) and uses mean ± 1.96 SD. CLSI recommends the non-parametric method, although an IFCC multicentre study found the two methods gave very close results. Minimum sizes quoted in the guidance: 120 per partition, so 240 for separate male and female intervals. The IFCC multicentre protocol sets a minimum of 500 per country.
Interactive
Change the number of healthy people and watch how precise the reference limits become
Each limit depends on the few most extreme values. With few people, those values change a lot from one study to the next.
Try this: start at 40 healthy people and look at how far apart the 40 upper limits (red dots) lie. Then choose 120 and 480 and watch them close in on the true upper limit.
Teaching simulation with a made-up enzyme whose healthy values are skewed to the right. The true central 95% of the whole healthy population is 11.4 to 54.8 U/L. Each dot is one reference interval study of the size you choose.
● lower limit of each study red: upper limit of each study; shaded: middle 90% of the 40 studies
With 40 healthy people per study, 90% of the studies put the upper limit between 46.5 and 76.9 U/L (true value 54.8), and the lower limit between 8.0 and 14.3 U/L (width 6.3; true value 11.4).
The upper limit varies more than the lower one because the values are skewed to the right: the few highest results lie far apart.
Decide
Can you use the reference interval from the kit insert or another laboratory?
Establishing an interval is expensive. CLSI EP28-A3c allows a laboratory to adopt an existing interval if it checks that the interval fits its own method and population.
Is there already a reference interval for this test, from the manufacturer or another laboratory?
Establish, transfer or verify: all possible answers
- Establish your own interval: Recruit at least 120 reference individuals per partition, take the 2.5th and 97.5th percentiles by the non-parametric method, and give 90% confidence intervals for both limits.
- Consider an indirect method: Indirect methods estimate the interval from results already in the laboratory database. They are used for groups such as children and the elderly, with less control over who was sampled and how.
- Verify with 20 local healthy people: If no more than 2 of 20 results fall outside the interval, adopt it. If more than 2 fall outside, test another 20. If 3 or more fall outside again, re-examine the method and the populations.
- Transfer by method comparison, then verify: Compare the two methods on the same samples, convert the limits by linear regression, and check that the reference populations are comparable. Then verify with 20 local healthy people.
- Transference: when the method changes, compare the new and old methods (similar imprecision, known interferences, the same or comparable calibrators, comparable values) and transfer the limits by linear regression. The reference populations must also be comparable.
- Verification: test 20 healthy people from your own population. If no more than 2 of 20 results (10%) fall outside the interval, adopt it, at least provisionally. If more than 2 fall outside, test a second 20. If 3 or more fall outside again, re-examine the analytical procedure and the biological differences between the populations.
Comparison
Is a result outside the reference interval abnormal?
Not necessarily. By definition, 5% of results from healthy people fall outside the reference interval. A clinical decision limit answers a different question.
| Feature | Reference interval | Clinical decision limit |
|---|---|---|
| Describes | The central 95% of a healthy reference population | A threshold above or below which a specific medical decision is recommended |
| Derived from | Reference values: percentiles of healthy people | Clinical studies, ROC curves and predictive values |
| Specific to | The population and the method | The diagnostic question |
| Example | Laboratory interval for HDL cholesterol in healthy adults | HbA1c 6.5% for diagnosing diabetes |
| On the report | In the reference interval column | Stated clearly as a decision limit, for example as a comment. C28-A3 recommends reporting one or the other, with a clear indication of which is used |
Before and after the analyser
What else affects the quality of a test report?
IQC and EQA check the analytical phase. Most laboratory errors happen before the sample reaches the analyser or after the result leaves it.
| Phase | Variables that affect the result |
|---|---|
| Pre-analytical | Test request, patient preparation (fasting, time of day, exercise), collection technique and tube additive, tourniquet, labelling, haemolysed, lipaemic or contaminated samples, transport, centrifugation, storage |
| Analytical | Method and calibration, reagent lot and storage, expired or deteriorated reagents, pipetting, incubation time and temperature, washing, equipment failure, interference (especially in immunoassays), carry-over, calculation errors |
| Post-analytical | Transcription errors, wrong reference interval on the report, delayed or misread reports |
In a real paper
Sigma metrics and reference intervals in Indian laboratories
Kumar BV, Mohan T. Sigma metrics as a tool for evaluating the performance of internal quality control in a clinical chemistry laboratory. J Lab Physicians. 2018;10(2):194–9.
doi:10.4103/JLP.JLP_102_17 · PMID 29692587 · Free full text (PMC5896188)
The study: A retrospective study in a secondary care government hospital in Chennai. The authors took one year of internal QC and EQAS data for 16 biochemistry tests, calculated a sigma metric for each test and control level, and used it to choose Westgard rules and the number of control levels.
“Where, TEa is total error allowable, Bias and CV are the indicator of systematic and random errors, respectively.”
The authors calculated sigma = (TEa − bias) ÷ CV. TEa is how much total error the test is allowed. Bias is the systematic part, taken from their EQA results. CV is the random part, taken from repeated internal QC results. Sigma counts how many CVs fit into the allowance left after the bias.
| Reported | Value | What it means |
|---|---|---|
| Tests | 16 | biochemical parameters on a VITROS 4600 analyser |
| Period | July 2015 to June 2016 | one year of routine QC data |
| TEa | CLIA-88 Proficiency Testing Criteria | the quality requirement used for every test |
| Bias and CV | Bio-Rad EQAS and Bio-Rad internal QC | systematic error from EQA, random error from IQC |
| QGI | Bias/1.5 × CV% | below 0.8: imprecision. Above 1.2: inaccuracy |
| ≥6 sigma at both levels | ALP, magnesium, triglyceride, HDL | one level of QC per day and the 1-3 s rule alone |
| <3 sigma at level 2 | urea, albumin, cholesterol, potassium | root cause analysis and method improvement before routine use |
- The TEa source decides the sigma. The same data with a biological variation or RiliBÄK goal would give different values.
- Sigma was calculated separately for each control level, and some tests (AST, ALT) differed between levels.
- The conclusion names magnesium as a problem analyte, while the results place magnesium at 6 sigma or more and potassium below 3. Compare the text with the tables.
- The formula as printed does not say that the absolute value of bias is used.
Sabnis K, Ghanghurde S, Shukla A, Sukheja D, Rojekar MV. An Indian perspective for umbilical cord blood haematological parameters reference interval. BMC Pediatr. 2023;23(1):287.
doi:10.1186/s12887-023-04090-2 · PMID 37291518 · Free full text (PMC10249286)
The study: A cross-sectional study in a tertiary care hospital in Maharashtra that established cord blood haematology reference intervals for healthy term newborns, because adult intervals do not apply to neonates and no Indian cord blood intervals existed.
“As per the Clinical Laboratory Standard Institute (CLSI) guideline C28-A3, about 120 samples per partition is required to determine the 95% reference interval”
CLSI C28-A3 is the earlier name of EP28-A3c. A partition is a subgroup that gets its own interval, such as boys and girls. About 120 samples per partition is the minimum for estimating the 2.5th and 97.5th percentiles with confidence intervals. The 95% reference interval is the central 95% of healthy babies' values.
| Reported | Value | What it means |
|---|---|---|
| Neonates | 127 | healthy term babies, October to December 2022 |
| Sex | 68 (53.5%) males and 59 (46.5%) females | each sex alone is below 120 |
| Limits | 2.5th and 97.5th percentiles | non-parametric central 95% |
| Haemoglobin | 14.7 [8.08–21.44] g/dL | median [95% reference interval] |
| Platelets | 249 [16.97–479.46] × 10⁹/L | median [95% reference interval] |
- The total of 127 is just above 120, but the sex-specific intervals rest on 68 and 59 babies.
- Look for how outliers were identified before the percentiles were taken. A lower platelet limit of 16.97 × 10⁹/L in healthy babies needs that check.
- Look for 90% confidence intervals around each limit.
- All babies came from one hospital. The authors list this and the smaller sample size as limitations.
How to run it
How do you draw control charts and calculate reference intervals in software?
For a thesis or an audit you may need to reproduce a control chart or calculate a reference interval yourself. Each step below was checked in the official documentation.
IBM SPSS Statistics (Statistics Base)
- Analyze > Quality Control > Control Charts.
- Select Individuals, Moving Range, choose the data organisation, and click Define.
- Move the control results into Process Measurement, and a run or date variable into Subgroups Labeled By.
- Click Control Rules to flag out-of-control points. The SPSS rule list (for example, greater than +3 sigma, 2 points out of the last 3 greater than +2 sigma, 8 consecutive points above the centre line) is not the Westgard multirule set, so check the rules you select.
R
library(qcc) # CRAN package qcc, version 2.7
baseline <- c(98, 101, 103, 99, 100, 97, 102, 104, 100, 96,
101, 99, 103, 98, 100, 102, 97, 101, 99, 100)
new_runs <- c(101, 99, 105, 106, 100, 98, 93, 102, 104, 103, 103, 104, 97, 95)
# centre and SD fixed from the baseline, limits at 3 SD (nsigmas = 3 is the default)
qcc(new_runs, type = "xbar.one", center = mean(baseline), std.dev = sd(baseline))
library(referenceIntervals) # version 1.3.1
# non-parametric interval (RI = "n") with non-parametric 90% CIs (CI = "n", needs n of 120 or more)
refLimit(values, out.method = "horn", out.rm = FALSE, RI = "n", CI = "n",
refConf = 0.95, limitConf = 0.90)
library(refineR) # version 2.0.0: indirect method from routine results
fit <- findRI(Data = routine_results)
getRI(fit, RIperc = c(0.025, 0.975))In referenceIntervals, out.rm = FALSE detects outliers without removing them. With fewer than 120 values, refLimit uses bootstrapping for the confidence intervals. jamovi: no control chart or reference interval analysis in the core program could be verified, so no jamovi steps are given.
How to report it
What should you write in a thesis or audit report?
Give enough detail for a reader to repeat the QC decision or the interval: the materials, the numbers, the rules and the sources of every target.
- IQC: control materials (manufacturer or third party, levels), how the mean and SD were set (number of measurements, days), the rules, N per run, and the frequency.
- Sigma: TEa and its source, where bias and CV came from, the period, and the level of control.
- EQA: the scheme, number of cycles, and z-score or SDI per cycle.
- Reference interval: selection criteria for reference individuals, pre-analytical conditions, method, n per partition, outlier method, parametric or non-parametric estimation, and 90% confidence intervals for each limit (recommended by IFCC since 1987).
Worked sentence (teaching numbers): “Glucose was monitored with a third-party level 1 control in every run. The control mean (100.0 mg/dL) and SD (2.18 mg/dL, CV 2.2%) were set from 20 baseline measurements. Runs were judged with 1-3s/2-2s/R-4s/4-1s/10x rules. With TEa 10% (source stated), bias 2.0% from EQA and CV 2.0% from IQC, the sigma metric was 4.0 (QGI 0.67). In the EQA cycle, creatinine gave z = 2.4 and corrective action was recorded. Reference limits were the 2.5th and 97.5th percentiles by the non-parametric rank method in 120 healthy adults per partition, with 90% confidence intervals.”
By specialty
Quality control and reference interval problems by specialty
Glucose, urea and creatinine run with two control levels on the same analyser. Some analytes reach 6 sigma, others stay below 3 sigma.
Calculate the sigma metric for each analyte and control level. Choose the control rules and the number of controls from it, instead of applying the full multirule to every test.
Anti-HIV, HBsAg and anti-HCV ELISA runs pass the kit controls every day.
Kit controls have a high positive value. A borderline-reactive in-house control plotted on a Levey-Jennings chart can show kit lot changes, operator changes and pipetting errors that the kit controls do not show.
An automated haematology analyser runs low, normal and high control material.
The Transfusion Medicine Technical Manual (2023) asks that control values lie within three SDs, with Levey-Jennings graphs kept by the analyser software.
Control plasmas for PT and APTT are reconstituted by hand each morning, and the normal-level control varies from day to day.
Rewarming, thawing, mixing and aliquoting of control material can make QC unstable. Standardise these steps before concluding that the analyser is at fault.
The report for a newborn prints the adult reference interval.
Adult intervals are unsuitable for newborns. Sabnis et al. (2023) derived cord blood intervals from 127 term babies in Mumbai.
HbA1c in a healthy pregnant woman is read against the interval for non-pregnant adults.
Punnose et al. (2023) found a median HbA1c of 4.8% in healthy pregnant women and 5.1% in non-pregnant women. Pregnancy needs its own reference values.
An HbA1c just above the laboratory's upper reference limit is written up as diabetes.
Diabetes is diagnosed at a decision limit of 6.5% HbA1c. A decision limit comes from clinical studies, not from the central 95% of healthy people.
The monthly interlaboratory report shows an SDI of +2.3 for one analyte.
An SDI of 2.0 or more calls for troubleshooting of bias and corrective action. Record what was found and what was changed.
Common myths
Common mistaken beliefs
Myth: If the controls pass, the patient results are correct.
IQC checks the analytical phase. In the Padova studies, most laboratory errors were pre-analytical (68.2% in 1996, 61.9% in 2006).
Myth: Any control beyond 2 SD means the run must be rejected.
In the multirule procedure, 1-2s is a warning. Used as a rejection rule with two controls, it rejects about 9% of good runs.
Myth: IQC detects only random error and EQA detects only systematic error.
IQC rules such as 2-2s, 4-1s and 10x detect systematic error. EQA mainly shows bias, but a single EQA result also contains that day's random error.
Myth: The reference interval on the kit insert can be used as it is.
CLSI EP28-A3c asks laboratories to verify it with 20 healthy people from their own population, or to establish their own.
Myth: A result outside the reference interval means disease.
5% of results from healthy people fall outside the interval. Diagnosis uses decision limits from clinical studies.
Myth: A test with a high sigma needs more QC.
The opposite. At 6 sigma, one 1-3s rule with two controls is enough. Below 4 sigma, more rules and more controls are needed.
Why this matters to you
Five consequences of getting laboratory QC wrong
Wrong results released
Releasing results after a broken rejection rule sends patients' results with a known error to the ward. The NBTC guidelines require laboratories to prevent release when IQC fails.
Good runs thrown away
Rejecting every run with a result beyond 2 SD wastes reagents, time and samples on about 9% of runs that had nothing wrong.
Failed EQA and accreditation
Participation in EQA is often an accreditation requirement. An unexplained bias found in EQA must be investigated and corrected.
Misclassified patients
Adult intervals applied to newborns, or non-pregnant intervals applied in pregnancy, label healthy patients abnormal and miss real abnormalities.
Questions you cannot answer
Westgard rules, IQC, EQA and reference intervals have been set repeatedly in MD Biochemistry and Transfusion Medicine papers since 2011.
History
History of laboratory quality control and reference intervals
- 1924
Walter A. Shewhart
In a memorandum of 16 May 1924 at Western Electric, he proposed the statistical control chart to separate chance-cause from assignable-cause variation.
- 1931
Walter A. Shewhart
Published Economic Control of Quality of Manufactured Product.
- 1950
S. Levey and E. R. Jennings
Published "The use of control charts in the clinical laboratory" in the American Journal of Clinical Pathology.
- 1952
R. J. Henry and M. Segalove
Described the running of standards in clinical chemistry and the use of the control chart in the Journal of Clinical Pathology.
- 1977
J. O. Westgard and colleagues
Published the probabilities of false rejection and error detection for internal quality control rules.
- 1981
Westgard, Barry, Hunt and Groth
Published "A multi-rule Shewhart chart for quality control in clinical chemistry", the basis of the Westgard rules.
- 1986
Bill Smith, Motorola
Introduced the Six Sigma quality improvement method at Motorola.
- 1987–1991
IFCC
Published a series of six papers recommending defined procedures for each laboratory to produce its own reference values.
- 2000
Medical laboratories
The first paper expressing laboratory processes on the sigma scale was published.
- 2008
CLSI and IFCC
Published guideline C28-A3 on defining, establishing and verifying reference intervals, now EP28-A3c, reaffirmed without revision in April 2020.
- 2024
Dte.GHS, Blood Transfusion Services
Issued the first edition of the Operational Guidelines for National External Quality Assessment Programme for Blood Centres in India.
Guidelines
Quality control and reference intervals in guidelines
“The laboratory shall prevent the release of test results in the event that IQC fails the defined acceptability criteria.” IQC material is chosen for stability, a matrix close to test samples, a similar reaction to the method, and levels at or near decision limits.
“At least three test events for both TTI and IH should be distributed each year in order to permit an adequate assessment of laboratory procedures and practices and to gather sufficient data for cumulative performance monitoring.”
“Internal quality control should be complemented by participation in the External Quality Assurance Programme.”
At least 120 subjects per group are required to calculate confidence intervals for the lower and upper limits. An existing interval may be adopted if no more than 2 of 20 local reference samples fall outside it.
R-4s: “this rule should only be interpreted within-run, not between-run.”
Reading a paper
Five checks on a QC or reference interval study
- Is the source of TEa stated, and would another source change the sigma values?
- Were CV and bias taken from the same period and the same control level?
- For a reference interval: how many reference individuals per partition, and were they selected with stated exclusion criteria?
- Are the outlier method, the estimation method (parametric or non-parametric) and 90% confidence intervals reported?
- Is a reference interval being used as if it were a decision limit, or the other way round?
Why is it called that?
Word surgery
“Control”
Power over something, keeping it in check.
A sample with an established expected range, run with patient samples so that the run can be accepted or rejected.
“Normal”
Healthy, nothing wrong.
Within the reference interval. By definition 5% of healthy people are outside it.
“Bias”
Prejudice, favouring one side.
The systematic difference between the laboratory's results and the true or target value.
Random error: 1-3s and R-4s. Systematic error: 2-2s, 4-1s and 10x. 1-2s is only a warning.
Control
Medieval Latin contrarotulus: "a counter, register", from contra "against" + rotulus "roll"
The word came from checking accounts against a duplicate register. A control sample is checked against its established range.
Proficiency
Latin proficere: "make progress, be useful"
Proficiency testing checks how well a laboratory performs on samples sent by an external provider.
Reference
Latin referre, through Medieval Latin referentia: "act of referring"
A reference interval is what a patient's result is referred to: values from healthy reference individuals.
Sigma
the Greek letter σ, the symbol for standard deviation
Six Sigma means six SDs of the process fit within the tolerance limits.
Levey-Jennings chart
named after S. Levey and E. R. Jennings, 1950
Their 1950 paper described the use of control charts in the clinical laboratory.
Exam answers
Model answer outlines
Westgard multirule QC rules, their interpretation, and two rules that detect random error
MD Biochemistry 2014, 2015, 2016, 2020, 2022 · MD Immuno Haematology and Blood Transfusion 2022- Origin: Westgard, Barry, Hunt and Groth, Clinical Chemistry 1981, a multirule Shewhart chart. Control results are plotted on a Levey-Jennings chart with lines at the mean ± 1, 2 and 3 SD.
- Rules: 1-2s warning (one result beyond 2 SD). Rejection rules: 1-3s (one beyond 3 SD, random), 2-2s (two consecutive beyond the same 2 SD limit, systematic), R-4s (one beyond +2 SD and one beyond −2 SD within a run, random), 4-1s (four consecutive beyond the same 1 SD limit, systematic), 10x (ten consecutive on one side of the mean, systematic).
- Two rules for random error: 1-3s and R-4s.
- Interpretation: both results within 2 SD: accept. A 1-2s warning: inspect with the rejection rules. Any rejection rule broken: reject the run, do not report results. 1-3s, 2-2s and R-4s can be applied within a run. 4-1s and 10x usually across runs and materials. R-4s only within a run.
- Action: identify the error type from the rule, troubleshoot, correct, re-run controls, repeat patient samples since the last acceptable run.
- Why multirule: 2 SD limits alone with two controls reject about 9% of good runs. 3 SD limits reject few good runs but miss errors. Combining rules keeps false rejection low and error detection high.
- Variations: 2of3-2s, 3-1s, 6x, 9x for three control materials. Computer applications do not need the 1-2s warning. Westgard Sigma Rules select rules from the sigma metric.
Internal quality control programme: requirements, choice of control material, monitoring and interpretation
MD Biochemistry 2015, 2017, 2020, 2025 · MS OBSTETRICS AND GYNAECOLOGY 2015- Definition: sample material and procedures that verify the intended quality of results, monitor day-to-day reproducibility and detect major analytical errors.
- Requirements: written SOP, trained staff, calibrated equipment, suitable control material, defined rules and acceptance criteria, records, review and corrective action, and participation in EQA.
- Criteria for control material: stable, matrix as close as possible to patient samples, reacts to the method like patient samples, levels at or near decision limits (two or three levels), third-party material considered, lot changes not on the same day as reagent or calibrator lot changes.
- Setting up: at least 20 measurements over at least 10 days. Calculate mean, SD and CV. Draw the Levey-Jennings chart at mean ± 1, 2, 3 SD.
- Frequency: based on the stability of the method and the risk of harm from an erroneous result. Sigma metrics can set rules, N and frequency.
- Monitoring: plot every result, apply Westgard rules, record so that trends and shifts are detectable, review at regular intervals.
- Interpretation: accept, warning, or reject. When IQC fails, prevent release, correct the error, re-examine samples, and evaluate results since the last successful IQC event.
- Example: glucose control mean 100.0, SD 2.18. Results 105 then 106 mg/dL: 2-2s, systematic error, run rejected.
Quality control charts
MD Biochemistry 2018- Principle (Shewhart, 1924): separate chance-cause (common-cause) variation from assignable-cause (special-cause) variation by plotting results in time order against limits.
- Shewhart chart types: mean and range charts for measurements, and np, p, c and u charts for counts.
- Levey-Jennings chart (1950): individual control results plotted against the mean ± 1, 2, 3 SD of that control. Construction and worked example as in this chapter.
- Multirule Shewhart chart (Westgard 1981): several rules applied to the Levey-Jennings chart.
- Cusum chart: plots how results deviate cumulatively above or below the target. It is useful for detecting small, persistent changes in the mean.
- EWMA chart: an exponentially weighted moving average chart, also available in the R package qcc.
- Interpretation: points beyond limits and non-random patterns (shifts, trends) indicate error. Control limits come from the method's own data, unlike TEa, which is a quality requirement.
Levey-Jennings chart in transfusion transmitted disease testing
MD Immuno Haematology and Blood Transfusion 2020- Why: ELISA kit controls have a high positive value and give only single-point calibration. They cannot monitor batch-to-batch variation, gradual equipment failure or reagent deterioration.
- IQC sample (Dubey and Sonker 2021): a donor sample reactive for one marker and non-reactive for others, diluted with normal serum to a borderline E-ratio of 1.5 to 2.0, split into aliquots, checked for CV below 10%, and stored frozen.
- Value plotted: E-ratio = OD of the control ÷ cut-off OD, one IQC sample per run, tested like a donor sample.
- Chart: mean and ± 1, 2, 3 SD from the aliquot results. 30 runs per chart, labelled with kit name, lot and expiry, equipment and operator.
- Rules used: one control beyond 2 SD (warning), two consecutive beyond 2 SD (systematic), one beyond 3 SD (random), four consecutive beyond 1 SD on one side (systematic), six consecutive on one side (shift) and six consecutive rising or falling (trend).
- Findings: 11 violations in 540 runs (2.03%). Causes included an erroneously used different kit lot, a change of operator, a wrongly calibrated pipette, a deteriorated control aliquot and a sample mix-up.
- Also: kit internal and external controls must be included in each ELISA run (Transfusion Medicine Technical Manual 2023), and IQC must be complemented by EQA.
Internal quality control is a measure of random error whereas external quality control is a measure of systematic error: justify
MD Biochemistry 2015- IQC and random error: the same control is measured repeatedly in the same laboratory, so its SD and CV measure imprecision. Rules 1-3s and R-4s detect random error.
- EQA and systematic error: the laboratory's result is compared with an assigned value or the peer-group mean, so the difference (z-score, SDI, bias%) measures systematic error. In sigma metric studies, bias is taken from EQA and CV from IQC.
- Limits of the statement: IQC also detects systematic error through the 2-2s, 4-1s and 10x rules and through shifts and trends on the chart. A single EQA result also contains that day's random error, and a large CV index in a peer report points to imprecision.
- Conclusion: IQC mainly monitors precision and stability run by run, and EQA mainly shows accuracy relative to other laboratories. The two are complementary.
Role of external quality assessment in transfusion medicine
MD Immuno Haematology and Blood Transfusion 2015- Definition: external evaluation of performance using known but undisclosed panel samples at periodic intervals, allowing comparison with other laboratories and corrective and preventive action.
- For the blood centre: identifies process problems, gives an objective view of performance relative to other centres, detects errors in TTI testing and immunohaematology, and allows a peer review of technical and methodological problems.
- For patients: errors such as a false negative TTI result are found and corrected, so blood is safer.
- For authorities: objective data on quality for accrediting and regulatory bodies, setting standards, reviewing testing strategies, post-market surveillance of kits, reagents and instruments, and public confidence.
- Education: training of staff, advice to poor performers, and comparability of results among blood centres.
- In practice: the EQAS sample is run with routine samples, and every technical staff member should test and interpret it. IQC must be complemented by EQA.
- India: NEQA operational guidelines for blood centres (2024), at least three test events a year for TTI and IH.
Salient features of the recent Guidelines for National External Quality Assessment Programme for Blood Centres in India
MD Immuno Haematology and Blood Transfusion 2025Operational Guidelines for National External Quality Assessment Programme for Blood Centres in India, first edition 2024, Blood Transfusion Services, Dte.GHS, MoHFW. Salient features are listed in the table in the NEQA section. In an answer, group them as:
- Aims and scope: nationwide EQA, organising centres, performance evaluation, common errors and corrective measures, harmonisation, and later extension to quality control of blood components.
- Operational requirements for participants: valid blood centre licence, infrastructure, trained personnel, equipment with maintenance contracts.
- Structure: Dte.GHS as national coordinating centre, advisory committee, nodal centres as PT providers for two or more states, SRBC in each state, and sample-providing centres of excellence.
- PT management: markers for TTI and IH, at least three test events a year, sample numbers and volumes, stability, packaging and transport, 4 to 6 week turnaround, and a pilot cycle in at least ten government licensed blood centres.
- Scoring and monitoring: TTI 100 marks (25 kit information, 75 results), IH 500 marks (25 and 475), z scores for quantitative data, satisfactory, borderline and unsatisfactory categories, cumulative scores, non-punitive follow-up.
- Quality management: IQC with control charts, prevention of release when IQC fails, documentation, nonconforming work and corrective action, budget and subscription fees.
External quality assessment in laboratory haematology
DM Clinical Haematology 2022- Definition and aims: as above. EQA gives information on test accuracy and long-term laboratory performance. It is often an accreditation requirement.
- Forms: proficiency testing (distribution of samples for analysis), interlaboratory peer comparison of IQC data, and educational exercises such as case series and expert advice.
- Haematology and haemostasis schemes: for example UK NEQAS (Blood Coagulation), RCPAQAP Haematology and the ECAT Foundation. In India, haemoglobin is an EQA parameter for blood centres.
- Evaluation: z-score = (result − participant mean) ÷ participant SD. SDI = (lab mean − group mean) ÷ group SD: within ±1.0 acceptable, 1.0 to 1.9 investigate, 2.0 or more troubleshoot bias. CV index = lab CV ÷ group CV: above 1.5, troubleshoot imprecision.
- Problems: when 11 EQA organisations graded the same aPTT and factor VIII results from 218 laboratories, pass or fail grades disagreed for 11% to 20.2% of results, although all used ISO 13528-compliant statistics. Harmonisation of EQA practice has been proposed.
- Response to poor performance: investigate pre-analytical, analytical and clerical causes, take corrective action, and review IQC for the same period.
Internal quality control for plasma clotting times
DM Clinical Haematology 2018- Requirement: IQC for routine and specialist haemostasis tests is mandatory under ISO, US Code of Federal Regulations and CLSI standards.
- Material: control plasma at a normal level and an abnormal level for PT, APTT, thrombin time and fibrinogen. Sources: the reagent supplier, a third party, or in-house.
- Frequency: per time period or per batch, as set by the laboratory.
- Handling: rewarming, thawing, mixing and aliquoting of control material can make QC unstable. Water for reconstituting lyophilised controls at 3–5°C produced significant bias in half of the IQC measurements tested. Standardise the water at 22–24°C.
- Monitoring: Levey-Jennings charts with defined acceptance criteria and Westgard rules. Sigma scores can be calculated for PT, APTT and fibrinogen, but with biological variation goals most were below 3.0, so rule selection by sigma needs fit-for-purpose goals.
- Troubleshooting: a written protocol for IQC failures, covering reagent, control material, instrument and operator, with patient samples repeated after correction.
- Complement: participation in a haemostasis EQA scheme.
Quality control in the laboratory and the variables that affect the quality of test reports
MD Biochemistry 2020- Quality system components: internal quality (process) control, proficiency testing or EQA, and quality improvement.
- Total testing process: pre-analytical, analytical and post-analytical phases. Most errors are pre-analytical (46–68.2%) and many are post-analytical (18.5–47%).
- Pre-analytical variables: test request, patient preparation (fasting, time of sampling, exercise), collection technique, tube and additive, tourniquet, labelling, haemolysis, lipaemia, transport, centrifugation, storage.
- Analytical variables: method, calibration, reagent lot and storage, pipetting, incubation, washing, instrument maintenance, interference, carry-over. Controlled by IQC, EQA and sigma-based QC design.
- Post-analytical variables: transcription errors, wrong reference interval, delayed or misread reports, confusion of reference intervals with decision limits.
- Tools: SOPs, training, Levey-Jennings charts and Westgard rules, EQA, quality indicators, documentation and corrective action.
Six sigma principles
MD Biochemistry 2017- Meaning: sigma is the SD. Six Sigma aims for six SDs of a process to fit within its tolerance limits. Anything outside is a defect.
- Origin: Motorola (Bill Smith, 1986) and General Electric. First applied to laboratory processes in a paper published in 2000.
- Defects: 6 sigma = 3.4 defects per million on the short-term scale (assuming a 1.5 SD long-term shift). 5 sigma = 233, 4 sigma = 6,210, 3 sigma = 66,807.
- Laboratory formula: sigma = (TEa% − |bias%|) ÷ CV%. Example: (10 − 2) ÷ 2 = 4.0.
- TEa sources (Milan 2015): clinical outcome, biological variation, state of the art (CLIA, RiliBÄK, RCPA, EQA goals).
- Grades: 6 world class, 5 excellent, 4 good, 3 marginal, 2 poor, below 2 unacceptable.
- Quality goal index: bias ÷ (1.5 × CV). Below 0.8 imprecision, above 1.2 inaccuracy.
- Uses: benchmarking methods and analysers, method selection (recommended for HbA1c by an IFCC working group), choosing Westgard rules and the number and frequency of controls.
Reference intervals: strategies for establishment (selection of reference individuals, specimen collection, quality control, statistical treatment)
MD Biochemistry 2011, 2016, 2017- Terms: reference individuals → reference sample group → reference values → reference distribution → reference limits → reference interval (usually central 95%). The term replaced “normal range”.
- Selection of reference individuals: defined health criteria, questionnaire, exclusion criteria, partition criteria (age, sex), informed consent. A priori or a posteriori sampling. Indirect methods from laboratory data for difficult groups.
- Specimen collection: standardise biological factors (time, fasting, activity) and methodological factors (technique, tubes, additives, tourniquet, handling, transport, centrifugation, storage).
- Analytical and QC: defined method and instrument, traceable calibrators, IQC with clear acceptance criteria throughout, and EQA.
- Statistics: inspect the distribution, remove outliers (Dixon D/R above 1/3, Tukey fences), decide partitions (Harris and Boyd, SD ratio above 0.3), non-parametric percentiles at ranks 0.025(n + 1) and 0.975(n + 1), or parametric after transformation, with 90% CIs.
- Sample size: at least 120 per partition (240 for both sexes). IFCC multicentre studies aim for at least 500 per country.
- Transference and verification: method comparison when methods differ. Verification with 20 local samples, no more than 2 outside.
- Reporting: state the population and method. Do not confuse reference intervals with clinical decision limits. Special intervals for children, the elderly and pregnancy.
The one thing to remember
Release a patient result only after the controls in that run have passed, and read the result against a reference interval built from enough healthy people like that patient.
Worked examples and interactive elements use made-up teaching data. Probabilities, sigma metrics, defects per million and the interactive elements were checked in Python (NumPy, SciPy).
Further reading: Indrayan A. Medical Biostatistics. Chapter on quality considerations. Jawlik AA. Statistics from A to Z: Confusing Concepts Clarified. Hoboken, NJ: Wiley; 2016.
Sources: Westgard JO, Barry PL, Hunt MR, Groth T. Clin Chem 1981;27(3):493–501 (PMID 7471403). Westgard JO et al. Clin Chem 1977;23:1857–67 (PMID 902411). Levey S, Jennings ER. Am J Clin Pathol 1950;20(11):1059–66 (doi:10.1093/ajcp/20.11_ts.1059). Henry RJ, Segalove M. J Clin Pathol 1952;5:305–11 (PMID 13011214). Best M, Neuhauser D. Walter A Shewhart, 1924, and the Hawthorne factory. Qual Saf Health Care 2006;15(2):142–3 (doi:10.1136/qshc.2006.018093). Westgard S, Bayat H, Westgard JO. Analytical Sigma metrics. Biochem Med 2018;28(2):020502 (doi:10.11613/BM.2018.020502). Kumar BV, Mohan T. J Lab Physicians 2018;10(2):194–9 (doi:10.4103/JLP.JLP_102_17). Hens K et al. Clin Chem Lab Med 2014;52(7):973–80 (doi:10.1515/cclm-2013-1090). Ozarda Y. Biochem Med 2016;26(1):5–16 (doi:10.11613/BM.2016.001). Ozarda Y, Higgins V, Adeli K. Clin Chem Lab Med 2018;57(1):30–7 (doi:10.1515/cclm-2018-0059). Theodorsson E. Biochem Med 2015;25(3):311–9 (doi:10.11613/BM.2015.031). Sabnis K et al. BMC Pediatr 2023;23(1):287 (doi:10.1186/s12887-023-04090-2). Punnose J et al. Sultan Qaboos Univ Med J 2023;23(1):81–9 (doi:10.18295/squmj.3.2022.022). Dubey A, Sonker A. Asian J Transfus Sci 2021;15(1):21–9 (doi:10.4103/ajts.AJTS_59_19). Reilly-Stitt C et al. Internal quality control in hemostasis assays. Semin Thromb Hemost 50(8):1084–90, epub 2023 (doi:10.1055/s-0043-1774381). De Nitto S et al. Diagnosis (Berl) 2020;8(2):233–8 (doi:10.1515/dx-2019-0111). Olson JD et al. Blood Coagul Fibrinolysis 2018;29(1):111–9 (doi:10.1097/MBC.0000000000000690). Hollestelle MJ et al. Clin Chem Lab Med 2019;57(8):1235–41 (doi:10.1515/cclm-2018-0934). Liang Y et al. Res Pract Thromb Haemost 2026;10(5):106834 (doi:10.1016/j.rpth.2026.106834). Favaloro EJ et al. Clin Chem Lab Med 2018;57(1):115–26 (doi:10.1515/cclm-2018-0077). Plebani M, Carraro P. Clin Chem 1997;43(8):1348–51 (PMID 9267312). Carraro P, Plebani M. Clin Chem 2007;53(7):1338–42 (doi:10.1373/clinchem.2007.088344). Plebani M. Clin Chem Lab Med 2006;44(6):750–9 (doi:10.1515/CCLM.2006.123). Blood Transfusion Services, Dte.GHS. Operational Guidelines for National External Quality Assessment Programme for Blood Centres in India, 1st ed. 2024. NBTC. Transfusion Medicine Technical Manual, 3rd ed. 2023. CLSI EP28-A3c. Westgard QC: “Westgard Rules” and Multirules, QC: The Levey-Jennings Control Chart, QC: The Multirule Interpretation, Westgard Sigma Rules (westgard.com). SLMTA Job Aid 2: Interpreting Comparison Reports. IBM SPSS Statistics documentation (Control Charts; RULES subcommand). CRAN reference manuals for qcc 2.7, referenceIntervals 1.3.1 and refineR 2.0.0. Accessed 15 September 2026.
Past papers
TNMGRMU questions on laboratory quality control and reference intervals
Questions from MD, MS, DM, MCh and Ph.D. papers that this chapter helps you answer. Tap a sitting to open the university's own question paper.
- ×3Westgard Multi QC rules and their interpretation
- ×2Westgard rules
- ×2Role of external quality assessment in transfusion medicine
- ×2Internal Quality Control
- ×1Enumerate the salient features of recent Guidelines for National External Quality Assessment Programme for Blood Centres in India
- ×1Internal quality control program in lab
- ×1External quality assessment in laboratory haematology
- ×1Levey-Jennings (LJ) chart in transfusion transmitted disease testing
- ×1Requirements for implementation of internal quality control programme in a laboratory . How to monitor and interpret the IQC values ?
- ×1Write briefly on quality control in laboratory. What are the variables that affect quality of the test reports?
- ×1Quality control charts
- ×1Internal quality control for plasma clotting times
- ×1Describe in detail the strategies for establishing reference intervals with respect to selection of reference individuals, specimen collection, Quality control procedures and statistical treatment of values
- ×1What are the criteria for choosing an internal quality control material and how will you interpret and monitor IQC values in your clinical chemistry lab?
- ×1Six sigma principles
- ×1Reference interval
- ×1Internal Quality Control is a measure of Random Error whereas external Quality Control is a measure of Systematic error – Justify
- ×1Name 2 Westgard rules that detect random error
- ×1Establishment of reference intervals
Further reading